99 related articles for article (PubMed ID: 32400319)
1. Biosimilars in Belgium: a proposal for a more competitive market.
Moorkens E; Vulto AG; Huys I
Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
[TBL] [Abstract][Full Text] [Related]
2. European Stakeholder Learnings Regarding Biosimilars: Part I-Improving Biosimilar Understanding and Adoption.
Barbier L; Simoens S; Vulto AG; Huys I
BioDrugs; 2020 Dec; 34(6):783-796. PubMed ID: 33141421
[TBL] [Abstract][Full Text] [Related]
3. Key drivers for market penetration of biosimilars in Europe.
Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
[No Abstract] [Full Text] [Related]
4. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
Río-Álvarez I; Cruz-Martos E
Expert Opin Biol Ther; 2024 Jun; ():1-15. PubMed ID: 38842367
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies.
Moorkens E; Jonker-Exler C; Huys I; Declerck P; Simoens S; Vulto AG
Front Pharmacol; 2016; 7():193. PubMed ID: 27445826
[TBL] [Abstract][Full Text] [Related]
6. What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
Busse A; Lüftner D
Breast Care (Basel); 2019 Mar; 14(1):10-16. PubMed ID: 31019437
[TBL] [Abstract][Full Text] [Related]
7. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
Coghlan J; He H; Schwendeman AS
J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
[TBL] [Abstract][Full Text] [Related]
8. Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany.
Moorkens E; Barcina Lacosta T; Vulto AG; Schulz M; Gradl G; Enners S; Selke G; Huys I; Simoens S
Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33096709
[TBL] [Abstract][Full Text] [Related]
9. Can Endangered Biosimilar Markets be Rescued? The Need to Bridge Competing Interests for Long-Term Gain.
Barcina Lacosta T; Vulto AG; Turk F; Huys I; Simoens S
BioDrugs; 2024 May; 38(3):325-329. PubMed ID: 38407791
[TBL] [Abstract][Full Text] [Related]
10. The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.
Kirshner G; Makai P; Brouns C; Timmers L; Kemp R
Eur J Health Econ; 2024 Jan; ():. PubMed ID: 38190008
[TBL] [Abstract][Full Text] [Related]
11. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review.
Machado S; Cruz A; Ferreira PL; Morais C; Pimenta RE
Front Public Health; 2024; 12():1263472. PubMed ID: 38481843
[TBL] [Abstract][Full Text] [Related]
12. Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting.
Wirth K; Boes S; Näpflin M; Huber C; Blozik E
BMJ Open; 2023 Nov; 13(11):e077454. PubMed ID: 37989386
[TBL] [Abstract][Full Text] [Related]
13. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?
Williamson R; Munro T; Ascher D; Robertson A; Pregelj L
Value Health; 2024 Mar; 27(3):287-293. PubMed ID: 38141814
[TBL] [Abstract][Full Text] [Related]
14. Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):237-250. PubMed ID: 38175140
[TBL] [Abstract][Full Text] [Related]
15. Charting the Etanercept Journey: Tracing Cost Dynamics in Poland's Off-Patent Market from Reference Drug Rivalry to Biosimilar Monopoly.
Stajszczyk M; Batko K; Żuber ZM; Kwiatkowska B; Krajewska-Włodarczyk M; Batko B
BioDrugs; 2024 Jun; ():. PubMed ID: 38861154
[TBL] [Abstract][Full Text] [Related]
16. The Importance of Countering Biosimilar Disparagement and Misinformation.
Cohen HP; McCabe D
BioDrugs; 2020 Aug; 34(4):407-414. PubMed ID: 32691270
[TBL] [Abstract][Full Text] [Related]
17. How to balance valuable innovation with affordable access to medicines in Belgium?
Simoens S; Abdallah K; Barbier L; Lacosta TB; Blonda A; Car E; Claessens Z; Desmet T; De Sutter E; Govaerts L; Janssens R; Lalova T; Moorkens E; Saesen R; Schoefs E; Vandenplas Y; Van Overbeeke E; Verbaanderd C; Huys I
Front Pharmacol; 2022; 13():960701. PubMed ID: 36188534
[No Abstract] [Full Text] [Related]
18. Short and long-term economic implications of biosimilars.
Al Meslamani AZ
Expert Opin Biol Ther; 2024 Jan; ():1-4. PubMed ID: 38231118
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review.
Fox GE; Bernauer M; Stephens JM; Jackson B; Roth JA; Shelbaya A
Clinicoecon Outcomes Res; 2024; 16():247-256. PubMed ID: 38765894
[TBL] [Abstract][Full Text] [Related]
20. Learnings from cross-border biosimilar pricing policies in Europe.
Simoens S; Lacosta TB; Inotai A
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):585-588. PubMed ID: 38530083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
